Genedrive Osake

Genedrive PEG

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Genedrive (GDR.L) 21.8.2026 päivämäärällä on −1,88.

PEG

−1,88

Viimeksi päivitetty:

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Genedrive on 2026 −1,88 . PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Genedrive oli 2025 0,00 . Se laskee % matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Genedrive Osakeanalyysi

Mitä Genedrive tekee? Genedrive PLC is a biomedical company based in Manchester, United Kingdom, specializing in the development of innovative diagnostic tests for infectious diseases and cancer. The company was founded in 2007 under the name Epistem Limited and went public in 2013. The business model of Genedrive involves developing and distributing innovative molecular diagnostic tests for diseases worldwide. The company's main goal is to change the way infectious diseases and cancer are diagnosed and treated by offering rapid, accurate, and cost-effective tests. The company has two main divisions: Genprobe and Instruments. Under Genprobe, various in vitro diagnostic tests for infectious diseases and diseases of the human immune system, including tuberculosis, hepatitis C, hepatitis B, HIV, and others, are offered. Under Instruments, Genedrive offers PCR instruments used for analyzing samples for DNA and RNA sequences. Some of Genedrive's key products include: - Genedrive HCV-ID Testkit: A test kit for identifying and quantifying hepatitis C viruses (HCV) in human blood samples. The test provides results within 90 minutes and has high accuracy. - Genedrive MT-RNR1 Testkit: A test kit for the rapid diagnosis of tuberculosis (TB), one of the most common infectious diseases worldwide. The test utilizes PCR technology and provides results within 90 minutes. - Genedrive Genedrive 96: An instrument for simultaneous analysis of up to 96 PCR samples. The system offers high accuracy and precision in analyzing RNA and DNA sequences. The company collaborates closely with leading research institutions and health organizations worldwide to improve its products and develop new tests. Genedrive has formed partnerships with the British government, the US Department of Defense, and other institutions. In recent years, the company has made significant progress in developing new diagnostic tests for infectious diseases and cancer. For example, Genedrive recently signed an agreement with the Foundation for Innovative New Diagnostics (FIND) to develop a molecular test for the Ebola virus. The company also has a pipeline of projects, including tests for COVID-19 and antibiotic resistance. Despite Genedrive's success, the company remains committed to innovation and research in order to transform the diagnostics industry and improve the health of people worldwide. Genedrive is expected to continue playing an important role in the fight against infectious diseases and cancer in the future. Genedrive on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Genedrive osakkeesta

Yhtiön Genedrive PEG-suhde (Hinta-tuotto-kasvu-suhde) on −1,88 vuonna 2026.

Eurpoolissa voit löytää PEG-suhde (Hinta-tuotto-kasvu-suhde) Genedrive:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

PEG-suhde korjaa P/E-suhteen odotetulla tuottojen kasvuvauhdilla. PEG alle 1 voi viitata osakkeeseen, joka on aliarvostettu suhteessa sen kasvupotentiaaliin.

PEG = P/E-suhde / Odotettu vuosittainen EPS-kasvuprosentti

Arvioidakseen PEG-suhde (Hinta-tuotto-kasvu-suhde):n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja PEG-suhde (Hinta-tuotto-kasvu-suhde):lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata PEG-suhde (Hinta-tuotto-kasvu-suhde):n Genedrive alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Genedrive

Kaikki tunnusluvut — Genedrive